October 21, 2017 8:39 AM ET

Pharmaceuticals

Company Overview of Polyphor Ltd

Company Overview

Polyphor Ltd., a pharmaceutical company, engages in the discovery and development of macrocycle drugs addressing high unmet medical needs. Its product pipeline includes CXCR4 antagonist POL6326, a potent and selective antagonist of the chemokine receptor CXCR4 that blocks the interaction with the ligand stromal cell-derived factor 1 resulting in the mobilization of stem cells from the bone marrow into the circulating blood; Antibiotic POL7080, a pseudomonas specific antibiotic with a novel mode of action; and Neutrophil elastase inhibitor POL6014, a selective and reversible inhibitor of human neutrophil elastase for the treatment of respiratory diseases, such as chronic obstructive pulmonary...

Hegenheimermattweg 125

Allschwil,  4123

Switzerland

Founded in 1996

Phone:

41 61 567 16 00

Fax:

41 61 567 16 01

Key Executives for Polyphor Ltd

Chief Executive Officer
Age: 63
Co-Founder and Chief Scientific Officer
Co-Founder and Director
Chief Financial Officer
Head of the Internal Services
Compensation as of Fiscal Year 2017.

Polyphor Ltd Key Developments

Polyphor Ltd Presents at Cambridge Healthtech Institute's 15th Annual Discovery on Target, Sep-25-2017 09:10 AM

Polyphor Ltd Presents at Cambridge Healthtech Institute's 15th Annual Discovery on Target, Sep-25-2017 09:10 AM. Venue: The Westin Copley Place, Boston, Massachusetts, United States. Speakers: Steffen Weinbrenner, Head of Drug Discovery.

Polyphor Names Kalina Scott as Chief Financial Officer, Effective from June 1St, 2017

Kalina Scott will join Polyphor as chief financial officer as of June 1st, 2017. She brings over 20 years of experience in the fields of mergers & acquisitions, capital markets and private placements in particular in the healthcare field, most recently as Managing Director, Corporate Finance with Bank am Bellevue in Zurich. Kalina started her career at UBS focusing on structured finance and credit risk management, followed by leading roles in UBS's investment banking in Zurich and London, covering leveraged finance as well as mergers & acquisitions, and in KPMG's Corporate Finance, where she built an IPO advisory unit.

Polyphor Presents Data for their Novel Class of Antibiotics

Polyphor presented promising data for their novel class of antibiotics, the Outer Membrane Protein Targeting Antibiotics (OMPTA). This is the first new class of antibiotic against Gram-negative pathogens to reach advanced clinical development in over 40 years. Murepavadin (POL7080), the first member of the OMPTA class ­ currently in Phase II and soon expected to enter Phase III - is being developed for the treatment of the most severe Pseudomonas aeruginosa (PA) infection ­ nosocomial pneumonia (including hospital-acquired and ventilator-associated pneumonia) - a disease with a death rate of 20%-50%. Early initiation of effective antimicrobial treatment for PA pulmonary infections is critical and a strong predictor of mortality. However, multi-drug resistant (MDR) PA has become a global problem and, as such, treatment is becoming more challenging with limited options available. Murepavadin, by means of its novel and unique mechanism of action, is extremely active and is being developed as first line treatment for MDR cases.

Similar Private Companies By Industry

Company Name Region
Acino International AG Europe
Activen SA Europe
AL-S Pharma AG Europe
Albea Pharmaceuticals AG Europe
Alpen Pharma AG Europe

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 12, 2017
--
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Polyphor Ltd, please visit www.polyphor.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.